Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rezolute Inc (NQ: RZLT )

2.890 +0.030 (+1.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 343,913
Open 2.860
Bid (Size) 1.890 (1)
Ask (Size) 3.120 (19)
Prev. Close 2.860
Today's Range 2.750 - 3.020
52wk Range 0.7200 - 3.690
Shares Outstanding 39,625,271
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire

Performance

YTD
+184.73%
+184.73%
1 Month
+52.91%
+52.91%
3 Month
+183.33%
+183.33%
6 Month
+206.08%
+206.08%
1 Year
+36.32%
+36.32%

More News

Read More
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Via InvestorPlace
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
Via Investor Brand Network
CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Expectations for Rezolute's Future
Via Benzinga
Expert Ratings for Rezolute
Via Benzinga
3 Stocks Insiders Are Buying That Analysts Love
Via MarketBeat
$17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
From Rezolute, Inc.
Via GlobeNewswire
Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Rezolute And 3 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
From Rezolute, Inc.
Via GlobeNewswire
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Via Newsfile
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports First Quarter Fiscal 2024 Results
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.